Obesity and its concomitant health risks are among the most common conditions managed by health care practitioners. The limited long-term effectiveness of conventional weight management has led to researching alternative medicine and one which is widely accepted is the herbal products by virtue of its safety in long term use. The study was conducted to evaluate effect of caplet of Garcinia extract with reference to reduction in BMI and skin fold thickness in obese individuals. This study was performed according to a double-blind, randomized, placebo-controlled, design. Subjects aged 18 to 60 years with Obesity as decided by BMI > 25 Kg/m 2 to 35 Kg/m 2 falling in the category of overweight and class I obesity were included in the study. A total of 110 individuals participated in the study. Subjects were randomly assigned into two groups of 55 each to receive treatment for 4 months with Garcinia or matching placebo at a dose of 1 caplet twice daily. All the subjects completed the study as stipulated. At the end of 4 months, Garcinia group had significant reduction in BMI and skin fold thickness when compared to the placebo group and baseline values respectively. No severe adverse effect was observed at any time in the study period. Compliance to treatment was good. It is therefore expected that Garcinia may be useful for the prevention and reduction of obesity.

Introduction. Haemorrhoids and anal fissures are considered as the most common anorectal conditions. Aim. To evaluate the safety and efficacy of Pilex Forte tablets in combination with Pilex Ointment as compared to the Standard of Care in common anorectal conditions Material and methods. Randomized, open-label, controlled comparative clinical study conducted on 162 patients of either sex, aged between 18-50 years, confirmed with common anorectal conditions. As per randomization, patients received either standard of care or Pilex Forte tablet along with Pilex Ointment at a recommended dose of two tablets twice daily and twice daily local application (anal) for a period of 4 weeks. Clinical safety and efficacy assessments were carried out at study specific scheduled visits. Laboratory assessments were carried out only at screening and at the end of the study. Results. Patients who completed the study were considered for statistical analysis. Significant clinical improvement was observed in patients with anorectal conditions who received Pilex Forte tablet and Pilex Ointment than to those who received standards of care. No abnormal lab values were recorded and there were no adverse events reported during the study period. Conclusion. Pilex Forte tablet along with Pilex Ointment at recommended dose is safe and effective in the management of anorectal conditions like haemorrhoids and fissure-in-ano.

Introduction. Non-alcoholic fatty liver disease (NAFLD) is excessive fat build-up in the liver due to causes other than alcohol use. Aim. To evaluate the clinical efficacy and safety of Liv.52 DS tablets in the management of NAFLD. Material and methods. Prospective, interventional clinical study conducted on 60 patients of both sex, aged between 18-65 years, confirmed with NAFLD from clinical examination, laboratory test, ultrasound findings and those willing to give informed consent. All patients received Liv.52 DS at a dose of 2 tablets twice daily for 2 months. All patients were evaluated at baseline, end of 1st month, and end of 2nd month for liver function tests, hepatomegaly by ultrasound, NAFLD Fibrosis Score, lipid profile, hematology and biochemical investigations. Results. Study data was analyzed with GraphPad Prism Software Version 6.07. Data of those patients who completed the study was considered for analysis. Significant improvement in hepatomegaly, liver enzymes was observed. NAFLD fibrosis score revealed no progression of liver fibrosis due to NAFLD during the study period. No abnormal lab values were recorded and there were no adverse events reported during the study. Conclusion. Study concludes that Liv.52 DS is safe and beneficial in individuals suffering from NAFLD.

No abstract